A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer

Phase 2 Active not recruiting 22 enrolled Dana-Farber Cancer Institute Eisai Inc. · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This research study is studying a drug called eribulin combined with standard treatment as a possible preoperative treatment for HER2 negative inflammatory breast cancer.

Timeline

Start: 2016-02-26
Primary completion: 2021-05
Completion: 2026-12

Publications

Fanucci K, Yeh ED, Shi R, Qin L, Bay CP, DiLullo M, Patel A, Moore M, Herbert ZT, Harrison BT, Nakhlis F, Bellon J, Warren L, Guerriero JL, Tolaney SM, Regan M, Overmoyer B, Van Laere S, Lynce F. Neoadjuvant therapy with eribulin, doxorubicin and cyclophosphamide for patients with HER2-negative inflammatory breast cancer: a phase II study. Breast Cancer Res. 2025 Sep 29;27(1):171. doi: 10.1186/s13058-025-02108-4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cyclophosphamide	Other / unclassified	—	Intravenous
Subject	Doxorubicin	Other / unclassified	—	Intravenous
Subject	Eribulin	Small molecule	—	Intravenous

A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer

Summary

Timeline

Publications

Drugs

Indications